12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Other News

KV Pharmaceutical genitourinary news

KV filed a complaint with the U.S. International Trade Commission seeking to prevent the import and sale of 17 alpha-hydroxyprogesterone caproate (17p), the active ingredient in KV's preterm birth drug...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >